Butterfly Network announced on Monday that it has secured U.S. regulatory approval for an innovative artificial intelligence-driven ultrasound device designed to estimate gestational age. This advancement is expected to enhance maternal healthcare accessibility, particularly in underserved regions.
Unlike conventional ultrasound machines that depend on costly piezoelectric crystals, Butterfly’s device employs a single silicon chip capable of whole-body imaging. The AI-powered tool can provide an estimate in less than two minutes without requiring users to capture or interpret images or conduct fetal biometric measurements.
The AI model powering the device was trained on over 21 million ultrasound images sourced from diverse patient groups and clinical environments. It is optimized to deliver reliable results for pregnancies ranging from 16 to 37 weeks.
In a significant development, this clearance aligns with the U.S. Food and Drug Administration’s ongoing encouragement of artificial intelligence integration in medical devices. The FDA highlights AI and machine learning’s potential to enhance healthcare by extracting novel insights from data generated during patient care.
Butterfly Network stated that the tool is embedded within its application and is designed to assist clinicians in making quicker decisions in emergency rooms, rural clinics, and other resource-limited settings. The company emphasized the persistent gaps in prenatal imaging access, noting that numerous rural counties in the U.S. lack hospital obstetric services.
Notably, the AI ultrasound tool has already been deployed in Malawi and Uganda, with plans underway to broaden its availability across the United States and additional international markets.
